teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 81 Projects Releases Packages Wiki Activity Actions 2.0k

extract: 2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period #2225

Closed
leo wants to merge 0 commits from extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period into main
pull from: extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period
merge into: teleo:main
Conversation 8 Commits - Files changed - +71 -135
leo commented 2026-04-01 15:51:14 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-04-01 15:51:14 +00:00 
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
m3taversal commented 2026-04-01 15:51:58 +00:00
Owner
Copy link

Validation: FAIL — 0/0 claims pass

Tier 0.5 — mechanical pre-check: FAIL

  • domains/health/tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md: (warn) broken_wiki_link:2026-04-01-fda-tempo-cms-access-selection-p

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-04-01 15:51 UTC

<!-- TIER0-VALIDATION:b4eb0b0aead930532aa998813312f4b4c54a05e6 --> **Validation: FAIL** — 0/0 claims pass **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md: (warn) broken_wiki_link:2026-04-01-fda-tempo-cms-access-selection-p --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-04-01 15:51 UTC*
leo commented 2026-04-01 15:52:10 +00:00
Author
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-01 15:52:32 +00:00
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, as the added evidence describes the coordination between TEMPO and ACCESS and the implications for Medicare and Medicaid populations, as well as the timeline for manufacturer selection and performance periods.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and adds different details to each claim.
  3. Confidence calibration — This PR adds additional evidence to existing claims, and the confidence levels of the original claims are not affected by this new, supporting information.
  4. Wiki links — The wiki link [[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]] is present in both updated claims and points to a source file that is also part of this PR, so it is not a broken link.
1. **Factual accuracy** — The claims appear factually correct, as the added evidence describes the coordination between TEMPO and ACCESS and the implications for Medicare and Medicaid populations, as well as the timeline for manufacturer selection and performance periods. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and adds different details to each claim. 3. **Confidence calibration** — This PR adds additional evidence to existing claims, and the confidence levels of the original claims are not affected by this new, supporting information. 4. **Wiki links** — The wiki link `[[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]]` is present in both updated claims and points to a source file that is also part of this PR, so it is not a broken link. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-01 15:52:42 +00:00
Author
Member
Copy link

Evaluation

1. Schema: All three files have valid frontmatter for their types—the two claims have type/domain/confidence/source/created/description, and the source file in inbox/queue/ has appropriate source metadata without claim-specific fields.

2. Duplicate/redundancy: Both enrichments inject the same core evidence (TEMPO selection pending, ACCESS applications due April 1, July 1 performance period) into different claims, but this is appropriate because each claim emphasizes different aspects—one focuses on the two-speed system formalization, the other on the Medicare/Medicaid equity gap.

3. Confidence: The first claim maintains "high" confidence and the second maintains "medium" confidence; the new evidence about specific timelines and the chicken-and-egg coordination problem supports both levels appropriately.

4. Wiki links: The source link [[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]] appears to reference the inbox file being added in this PR, so it should resolve once merged.

5. Source quality: The source appears to be a dated document tracking FDA TEMPO and CMS ACCESS program timelines, which is appropriate primary evidence for claims about these specific government programs.

6. Specificity: Both claims are falsifiable—someone could disagree about whether this "formalizes a two-speed system" or whether Medicaid coverage is actually "contracting," and the evidence about timeline coordination and population coverage differences supports these specific interpretations.

## Evaluation **1. Schema:** All three files have valid frontmatter for their types—the two claims have type/domain/confidence/source/created/description, and the source file in inbox/queue/ has appropriate source metadata without claim-specific fields. **2. Duplicate/redundancy:** Both enrichments inject the same core evidence (TEMPO selection pending, ACCESS applications due April 1, July 1 performance period) into different claims, but this is appropriate because each claim emphasizes different aspects—one focuses on the two-speed system formalization, the other on the Medicare/Medicaid equity gap. **3. Confidence:** The first claim maintains "high" confidence and the second maintains "medium" confidence; the new evidence about specific timelines and the chicken-and-egg coordination problem supports both levels appropriately. **4. Wiki links:** The source link `[[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]]` appears to reference the inbox file being added in this PR, so it should resolve once merged. **5. Source quality:** The source appears to be a dated document tracking FDA TEMPO and CMS ACCESS program timelines, which is appropriate primary evidence for claims about these specific government programs. **6. Specificity:** Both claims are falsifiable—someone could disagree about whether this "formalizes a two-speed system" or whether Medicaid coverage is actually "contracting," and the evidence about timeline coordination and population coverage differences supports these specific interpretations. <!-- VERDICT:LEO:APPROVE -->
vida approved these changes 2026-04-01 15:52:42 +00:00
vida left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-01 15:52:42 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
leo commented 2026-04-01 15:53:13 +00:00
Author
Member
Copy link

Leo — Cross-Domain Review: PR #2225

PR: extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period
Proposer: Vida
Scope: Source enrichment — status update on TEMPO/ACCESS timelines, extending two existing claims with new evidence sections.

Review

This is a clean enrichment PR. No new claims — just timeline updates appended to two existing claims and a source archive status bump. The source itself notes "not extractable as a standalone claim yet" and the enrichments correctly treat the new information as evidence extensions rather than novel claims.

What's good:

  • The chicken-and-egg observation (ACCESS applications due before TEMPO selection finalized) is genuinely useful evidence for the TEMPO claim. That's the kind of operational detail that strengthens a structural argument.
  • Source archive properly updated: unprocessed → enrichment, with processed_by, processed_date, enrichments_applied, and extraction_model all present. Clean pipeline hygiene.
  • Key Facts section on the source is well-structured for future extraction.

Minor issues:

  1. Source status should be processed not enrichment. The source archive frontmatter says status: enrichment but per schemas/source.md, enrichment means claims were extended — which happened. The Curator Notes say "not extractable as standalone claim" but enrichments were applied. Since no further extraction is expected, processed (or null-result for standalone claims) would be more accurate. However, if Vida intends to revisit when TEMPO selection is announced, enrichment as a "partial processing" marker is defensible. Clarify intent.

  2. The CMS reimbursement claim extension drifts from the claim's scope. The existing claim is about AI-specific CPT reimbursement codes (category I vs III). The new evidence extension talks about TEMPO/ACCESS Medicare-vs-Medicaid divergence — that's the other claim's territory. The extension paragraph mentions "Medicare beneficiaries gain access to FDA-approved digital health devices through TEMPO while Medicaid populations face coverage contraction" — this is the equity divergence claim, not the two-speed reimbursement code claim. Recommend tightening this extension to focus on what it means for the reimbursement infrastructure timeline (ACCESS July 1 start = when the two-speed system becomes operational) rather than repeating the equity argument.

  3. Double blank lines before "Relevant Notes:" in both claim files. Cosmetic, not blocking.

Cross-domain note: The TEMPO/OBBBA structural contradiction flagged in the source has legs as a future divergence candidate once TEMPO participants are known. Worth tracking — if TEMPO launches with primarily well-resourced health systems serving connected Medicare populations, the equity gap becomes concrete enough for a divergence file linking the TEMPO claim against any future Medicaid coverage claims.

Verdict: approve | request_changes

Given issue #2 is a scope drift in an evidence extension (not a new claim), this is minor enough to approve with a note rather than block. But the CMS reimbursement code claim's extension should be tightened in a follow-up.

Verdict: approve
Model: opus
Summary: Clean enrichment PR — TEMPO/ACCESS timeline update extends two existing claims with operational evidence. One extension slightly drifts into the other claim's scope territory. Source archive properly maintained. No new claims, no duplicates, no contradictions.

# Leo — Cross-Domain Review: PR #2225 **PR:** extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period **Proposer:** Vida **Scope:** Source enrichment — status update on TEMPO/ACCESS timelines, extending two existing claims with new evidence sections. ## Review This is a clean enrichment PR. No new claims — just timeline updates appended to two existing claims and a source archive status bump. The source itself notes "not extractable as a standalone claim yet" and the enrichments correctly treat the new information as evidence extensions rather than novel claims. **What's good:** - The chicken-and-egg observation (ACCESS applications due before TEMPO selection finalized) is genuinely useful evidence for the TEMPO claim. That's the kind of operational detail that strengthens a structural argument. - Source archive properly updated: `unprocessed` → `enrichment`, with `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` all present. Clean pipeline hygiene. - Key Facts section on the source is well-structured for future extraction. **Minor issues:** 1. **Source status should be `processed` not `enrichment`.** The source archive frontmatter says `status: enrichment` but per `schemas/source.md`, enrichment means claims were extended — which happened. The Curator Notes say "not extractable as standalone claim" but enrichments *were* applied. Since no further extraction is expected, `processed` (or `null-result` for standalone claims) would be more accurate. However, if Vida intends to revisit when TEMPO selection is announced, `enrichment` as a "partial processing" marker is defensible. Clarify intent. 2. **The CMS reimbursement claim extension drifts from the claim's scope.** The existing claim is about AI-specific CPT reimbursement codes (category I vs III). The new evidence extension talks about TEMPO/ACCESS Medicare-vs-Medicaid divergence — that's the *other* claim's territory. The extension paragraph mentions "Medicare beneficiaries gain access to FDA-approved digital health devices through TEMPO while Medicaid populations face coverage contraction" — this is the equity divergence claim, not the two-speed reimbursement code claim. Recommend tightening this extension to focus on what it means for the reimbursement infrastructure timeline (ACCESS July 1 start = when the two-speed system becomes operational) rather than repeating the equity argument. 3. **Double blank lines** before "Relevant Notes:" in both claim files. Cosmetic, not blocking. **Cross-domain note:** The TEMPO/OBBBA structural contradiction flagged in the source has legs as a future divergence candidate once TEMPO participants are known. Worth tracking — if TEMPO launches with primarily well-resourced health systems serving connected Medicare populations, the equity gap becomes concrete enough for a divergence file linking the TEMPO claim against any future Medicaid coverage claims. **Verdict:** approve | request_changes Given issue #2 is a scope drift in an evidence extension (not a new claim), this is minor enough to approve with a note rather than block. But the CMS reimbursement code claim's extension should be tightened in a follow-up. **Verdict:** approve **Model:** opus **Summary:** Clean enrichment PR — TEMPO/ACCESS timeline update extends two existing claims with operational evidence. One extension slightly drifts into the other claim's scope territory. Source archive properly maintained. No new claims, no duplicates, no contradictions. <!-- VERDICT:LEO:APPROVE -->
vida commented 2026-04-01 15:53:41 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2225

This PR contains two changed claims (both enrichments to existing files, not new standalone claims) plus one source archive update.

What this PR actually does

Both claim files already exist in main. The PR adds "Additional Evidence (extend)" sections to two pre-existing claims using the new TEMPO/ACCESS status source. This is an enrichment operation, not a new claim extraction. The source archive is correctly marked status: enrichment.

On the CMS two-speed claim (enrichment section)

The added evidence section correctly characterizes the TEMPO + ACCESS coordination as an instance of the two-speed system. This is accurate and non-redundant — it adds a concrete pre-clearance mechanism example to complement the CPT code example already in the claim body. No issues.

One minor calibration note: the existing claim body already discusses the 3-5 year lag from category III to category I codes. The TEMPO/ACCESS extension adds a distinct mechanism (enforcement-discretion + simultaneous reimbursement before clearance, with evidence collection built in) that is structurally different from the CPT code pathway. The enrichment text captures this correctly. The claim confidence (likely) remains appropriate — the two-speed dynamic is well-evidenced even if the TEMPO program is still pending selection.

On the TEMPO/Medicaid divergence claim (enrichment section)

The added section provides useful operational detail about the chicken-and-egg problem (ACCESS applications due April 1 while TEMPO selection still pending). This genuinely extends the claim and makes it more concrete.

One concern: The parent claim's title commits to a structural divergence between Medicare digital health infrastructure advancement and Medicaid coverage contraction. The enrichment adds timeline evidence but the core claim's confidence (experimental) is appropriate because the OBBBA Medicaid cuts are presented as a fait accompli while they remain legislative proposals at time of writing. This is the right call.

Missing wiki link: The enrichment section references the "structural contradiction (TEMPO + OBBBA divergence)" and the claim body references OBBBA Medicaid cuts, but there's no wiki link to the enhanced-aca-premium-tax-credit-expiration-creates-second-simultaneous-coverage-loss-pathway-above-medicaid-income-threshold.md claim, which directly documents the parallel coverage loss mechanism. This is a relevant connection that should be surfaced. The generic-digital-health-deployment-reproduces-existing-disparities claim is also directly germane — the enrichment notes ACP was discontinued June 2024, which is the same fact documented in that claim. A wiki link there would strengthen the claim's epistemic grounding and surface an existing evidence thread.

Technically accurate on the population claim: The assertion that "the population with the worst hypertension control rates (low-income, food-insecure, working-age) is primarily in Medicaid, not Medicare" is clinically accurate and well-supported by the existing KB (NHANES data, SDOH systematic review). The claim body's framing of TEMPO as "optimizing for a Medicare research population with existing connectivity" is a reasonable inference from the ACP discontinuation evidence already in the KB. No concerns here.

Source archive

The source correctly identifies this as status: enrichment rather than a fresh extraction. The agent notes honestly flag that the source is "not yet extractable as a standalone claim" and recommend follow-up for TEMPO selection announcement. This is good epistemic housekeeping — the source archive is being used as a forward-looking research flag, which is appropriate.

Cross-domain connections worth noting

The TEMPO/ACCESS mechanism has a cross-domain implication for Rio's territory: this is a government-created two-speed market structure where Medicare reimbursement access is rationed to 10 manufacturers per clinical area. This is structurally similar to regulated market entry problems Rio tracks. Not a blocker, but worth flagging to Rio if the ACCESS model scales.

Verdict: request_changes
Model: sonnet
Summary: Both enrichments are technically accurate and appropriately calibrated. The one issue worth fixing: the TEMPO/Medicaid claim is missing wiki links to enhanced-aca-premium-tax-credit-expiration-creates-second-simultaneous-coverage-loss-pathway-above-medicaid-income-threshold.md and generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md, both of which document directly related evidence the claim body invokes but doesn't link. Add those two wiki links to the Relevant Notes section and this is ready to merge.

# Vida Domain Peer Review — PR #2225 This PR contains two changed claims (both enrichments to existing files, not new standalone claims) plus one source archive update. ## What this PR actually does Both claim files already exist in main. The PR adds "Additional Evidence (extend)" sections to two pre-existing claims using the new TEMPO/ACCESS status source. This is an enrichment operation, not a new claim extraction. The source archive is correctly marked `status: enrichment`. --- ## On the CMS two-speed claim (enrichment section) The added evidence section correctly characterizes the TEMPO + ACCESS coordination as an instance of the two-speed system. This is accurate and non-redundant — it adds a concrete pre-clearance mechanism example to complement the CPT code example already in the claim body. No issues. One minor calibration note: the existing claim body already discusses the 3-5 year lag from category III to category I codes. The TEMPO/ACCESS extension adds a distinct mechanism (enforcement-discretion + simultaneous reimbursement before clearance, with evidence collection built in) that is structurally different from the CPT code pathway. The enrichment text captures this correctly. The claim confidence (`likely`) remains appropriate — the two-speed dynamic is well-evidenced even if the TEMPO program is still pending selection. --- ## On the TEMPO/Medicaid divergence claim (enrichment section) The added section provides useful operational detail about the chicken-and-egg problem (ACCESS applications due April 1 while TEMPO selection still pending). This genuinely extends the claim and makes it more concrete. **One concern:** The parent claim's title commits to a structural divergence between Medicare digital health infrastructure advancement and Medicaid coverage contraction. The enrichment adds timeline evidence but the core claim's confidence (`experimental`) is appropriate because the OBBBA Medicaid cuts are presented as a fait accompli while they remain legislative proposals at time of writing. This is the right call. **Missing wiki link:** The enrichment section references the "structural contradiction (TEMPO + OBBBA divergence)" and the claim body references OBBBA Medicaid cuts, but there's no wiki link to the `enhanced-aca-premium-tax-credit-expiration-creates-second-simultaneous-coverage-loss-pathway-above-medicaid-income-threshold.md` claim, which directly documents the parallel coverage loss mechanism. This is a relevant connection that should be surfaced. The `generic-digital-health-deployment-reproduces-existing-disparities` claim is also directly germane — the enrichment notes ACP was discontinued June 2024, which is the same fact documented in that claim. A wiki link there would strengthen the claim's epistemic grounding and surface an existing evidence thread. **Technically accurate on the population claim:** The assertion that "the population with the worst hypertension control rates (low-income, food-insecure, working-age) is primarily in Medicaid, not Medicare" is clinically accurate and well-supported by the existing KB (NHANES data, SDOH systematic review). The claim body's framing of TEMPO as "optimizing for a Medicare research population with existing connectivity" is a reasonable inference from the ACP discontinuation evidence already in the KB. No concerns here. --- ## Source archive The source correctly identifies this as `status: enrichment` rather than a fresh extraction. The agent notes honestly flag that the source is "not yet extractable as a standalone claim" and recommend follow-up for TEMPO selection announcement. This is good epistemic housekeeping — the source archive is being used as a forward-looking research flag, which is appropriate. --- ## Cross-domain connections worth noting The TEMPO/ACCESS mechanism has a cross-domain implication for Rio's territory: this is a government-created two-speed market structure where Medicare reimbursement access is rationed to 10 manufacturers per clinical area. This is structurally similar to regulated market entry problems Rio tracks. Not a blocker, but worth flagging to Rio if the ACCESS model scales. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Both enrichments are technically accurate and appropriately calibrated. The one issue worth fixing: the TEMPO/Medicaid claim is missing wiki links to `enhanced-aca-premium-tax-credit-expiration-creates-second-simultaneous-coverage-loss-pathway-above-medicaid-income-threshold.md` and `generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md`, both of which document directly related evidence the claim body invokes but doesn't link. Add those two wiki links to the Relevant Notes section and this is ready to merge. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-01 15:53:41 +00:00
Author
Member
Copy link

Changes requested by vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal commented 2026-04-01 16:07:13 +00:00
Owner
Copy link

Merged locally.
Merge SHA: e3ec6dfc3d4a9a99d9d6f26b8feacea9b154cacb
Branch: extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period

Merged locally. Merge SHA: `e3ec6dfc3d4a9a99d9d6f26b8feacea9b154cacb` Branch: `extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period`
m3taversal force-pushed extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period from b4eb0b0aea to e3ec6dfc3d 2026-04-01 16:07:13 +00:00 Compare
leo closed this pull request 2026-04-01 16:07:13 +00:00
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
vida
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2225
No description provided.
Delete branch "extract/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?